Table 2.
Grouping of in vivo primary study.
HA | MSC | VEGF | |
---|---|---|---|
Group 1—8 implants | 500 mg | 3 × 106 | 10 ng release/day |
Group 2—8 implants | 500 mg | 3 × 106 | 100 ng release/day |
Group 3—8 implants | 500 mg | 3 × 106 | 500 ng release/day |
Group 4—8 implants | 500 mg | Allograft | — |